Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29160321 | 1.00 | ALOX15 (0.43) | ALOX15LNPEPERAP2HDAC1SLC7A5 | |
| SCHEMBL26237173 | 0.89 | LNPEP (0.51) | LNPEPERAP2HDAC1MAPTNPC1 | |
| SCHEMBL23273557 | 0.86 | ALOX15 (0.42) | ALOX15LNPEPERAP2HDAC1SLC7A5 | |
| SCHEMBL26541098 | 0.83 | PRKCI (0.44) | LNPEPERAP2HDAC1MAPTNPC1 | |
| SCHEMBL25372434 | 0.83 | PTGER4 (0.49) | LNPEPERAP2MAPTNPC1RAB9A | |
| SCHEMBL25372438 | 0.83 | PTGER4 (0.49) | LNPEPERAP2MAPTNPC1RAB9A | |
| SCHEMBL23273555 | 0.80 | PTGER4 (0.57) | ALOX15LNPEPERAP2HDAC1SLC7A5 | |
| SCHEMBL3720352 | 0.80 | ALOX15 (0.46) | ALOX15LNPEPERAP2HDAC1SLC7A5 | |
| SCHEMBL23286842 | 0.78 | LNPEP (0.43) | LNPEPERAP2HDAC1AAK1MAPT | |
| SCHEMBL28353995 | 0.78 | LNPEP (0.53) | ALOX15LNPEPERAP2HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4520393-A2 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4271674-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4271674-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4271672-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230102927-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022225941-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022225914-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | ALOX15 3030/4885LNPEP 1751/4885ERAP2 1694/4885 |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | ALOX15 3030/4885LNPEP 1751/4885ERAP2 1694/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | ALOX15 3030/4885LNPEP 1751/4885ERAP2 1694/4885 |
| US-20240199589-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | ALOX15 3030/4885LNPEP 1751/4885ERAP2 1694/4885 |
| US-20230102927-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | ALOX15 3030/4885LNPEP 1751/4885ERAP2 1694/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | ALOX15 4535/4885LNPEP 1525/4885ERAP2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.